Literature DB >> 15869924

A generalized skeletal hyperostosis in two siblings caused by a novel mutation in the SOST gene.

Wendy Balemans1, Erna Cleiren, Ulrike Siebers, Jürgen Horst, Wim Van Hul.   

Abstract

In this study, a brother and sister of German origin are described with a possible diagnosis of van Buchem disease, a rare autosomal recessive sclerosing bone dysplasia characterized by a generalized hyperostosis of the skeleton mainly affecting the cranial bones. Clinically, patients suffer from cranial nerve entrapment potentially resulting in facial paresis, hearing disturbances, and visual loss. The radiological picture of van Buchem disease closely resembles sclerosteosis, although in the latter patients, syndactyly, tall stature, and raised intracranial pressure are frequently observed, allowing a differential diagnosis with van Buchem disease. Previous molecular studies demonstrated homozygous loss-of-function mutations in the SOST gene in sclerosteosis patients while a chromosomal rearrangement creating a 52-kb deletion downstream of this gene was found in Dutch patients with van Buchem disease. This deletion most likely suppresses SOST expression. Sclerostin, the SOST gene product, has been shown to play a role in bone metabolism. The two siblings reported here were evaluated at the molecular level by carrying out a mutation analysis of the SOST gene. This resulted in the identification of a novel putative disease-causing splice site mutation (IVS1 + 1 G-->C) homozygously present in both siblings.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15869924     DOI: 10.1016/j.bone.2005.02.019

Source DB:  PubMed          Journal:  Bone        ISSN: 1873-2763            Impact factor:   4.398


  19 in total

Review 1.  Inflammatory bone loss: pathogenesis and therapeutic intervention.

Authors:  Kurt Redlich; Josef S Smolen
Journal:  Nat Rev Drug Discov       Date:  2012-03-01       Impact factor: 84.694

2.  Identification of osteocyte-selective proteins.

Authors:  Dayong Guo; Andrew Keightley; Jill Guthrie; Patricia A Veno; Stephen E Harris; Lynda F Bonewald
Journal:  Proteomics       Date:  2010-10       Impact factor: 3.984

3.  A frameshift mutation in SANS results in atypical Usher syndrome.

Authors:  R Bashir; A Fatima; S Naz
Journal:  Clin Genet       Date:  2010-12       Impact factor: 4.438

4.  Advancing our understanding of osteocyte cell biology.

Authors:  Dayong Guo; Lynda F Bonewald
Journal:  Ther Adv Musculoskelet Dis       Date:  2009-04       Impact factor: 5.346

Review 5.  A review of osteocyte function and the emerging importance of sclerostin.

Authors:  Jocelyn T Compton; Francis Y Lee
Journal:  J Bone Joint Surg Am       Date:  2014-10-01       Impact factor: 5.284

Review 6.  Dynamics of the transition from osteoblast to osteocyte.

Authors:  Sarah L Dallas; Lynda F Bonewald
Journal:  Ann N Y Acad Sci       Date:  2010-03       Impact factor: 5.691

7.  Sclerostin antibody increases bone volume and enhances implant fixation in a rat model.

Authors:  Amarjit S Virdi; Min Liu; Kotaro Sena; James Maletich; Margaret McNulty; Hua Zhu Ke; Dale R Sumner
Journal:  J Bone Joint Surg Am       Date:  2012-09-19       Impact factor: 5.284

8.  Serum sclerostin: the missing link in the bone-vessel cross-talk in hemodialysis patients?

Authors:  S Pelletier; C B Confavreux; J Haesebaert; F Guebre-Egziabher; J Bacchetta; M-C Carlier; L Chardon; M Laville; R Chapurlat; G M London; M-H Lafage-Proust; D Fouque
Journal:  Osteoporos Int       Date:  2015-04-25       Impact factor: 4.507

9.  Relative influence of heritability, environment and genetics on serum sclerostin.

Authors:  A L Kuipers; Y Zhang; S Yu; C M Kammerer; C S Nestlerode; Y Chu; C H Bunker; A L Patrick; V W Wheeler; I Miljkovic; J M Zmuda
Journal:  Osteoporos Int       Date:  2013-10-18       Impact factor: 4.507

10.  Genetic analysis of vertebral trabecular bone density and cross-sectional area in older men.

Authors:  J M Zmuda; L M Yerges-Armstrong; S P Moffett; L Klei; C M Kammerer; K Roeder; J A Cauley; A Kuipers; K E Ensrud; C S Nestlerode; A R Hoffman; C E Lewis; T F Lang; E Barrett-Connor; R E Ferrell; E S Orwoll
Journal:  Osteoporos Int       Date:  2010-12-09       Impact factor: 4.507

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.